Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
N04BC
|
| gptkbp:CASNumber |
1350542-51-7
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Cerevel_Therapeutics |
| gptkbp:hasMolecularFormula |
C18H17Cl2N3O2
|
| gptkbp:hasSMILES |
CCN1C=CC(=N1)C2=C(C=CC(=C2)Cl)Cl
|
| gptkbp:hasUNII |
6Q1K1Q1K0E
|
| https://www.w3.org/2000/01/rdf-schema#label |
tavapadon
|
| gptkbp:isInClinicalTrialPhase |
Phase 3 (as of 2024)
|
| gptkbp:isInvestigationalDrugFor |
gptkb:Parkinson's_disease
|
| gptkbp:IUPACName |
1-[3-(2,6-dichlorophenyl)-1-ethyl-1H-pyrazol-5-yl]-3-(1-methyl-1H-pyrazol-4-yl)urea
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
dopamine D1/D5 receptor partial agonist
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71587741 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
PF-06649751
|
| gptkbp:bfsParent |
gptkb:Cerevel_Therapeutics
|
| gptkbp:bfsLayer |
6
|